A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2023 at "Hematological oncology"
DOI: 10.1002/hon.3159
Abstract: Relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) is a genetically complex and heterogeneous disease with a poor prognosis and limited treatment options. Thus, there is an urgent need to develop therapeutic combinations to overcome drug resistance… read more here.
Keywords: myeloid leukemia; refractory acute; relapsed refractory; alvocidib ... See more keywords
Abstract 1106: Alvocidib potentiates the activity of venetoclax in preclinical models of multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-1106
Abstract: The proteasome inhibitor bortezomib is widely used in the treatment of patients with multiple myeloma (MM). The expression levels of many proteins increase as a result of bortezomib treatment, including the pro-apoptotic protein NOXA. NOXA… read more here.
Keywords: mcl; alvocidib; treatment; activity venetoclax ... See more keywords